Abstract
This chapter will present clinical evidence for the efficacy of herbal treatments which address symptoms of anxiety primarily via their effects on cognitive functioning.
-
Brahmi (Bacopa monnieri)
-
Ginkgo (Ginkgo Biloba)
-
Lemon Balm (Melissa officinalis)
-
Tea (Camellia sinensis)
-
Sage (Salvia spp.)
-
Rosemary (Rosmarinus officinalis)
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ferreri F, Lapp LK, Peretti CS. Current research on cognitive aspects of anxiety disorders. Curr Opin Psychiatry. 2011;24:49–54.
O’Sullivan K, Newman EF. Neuropsychological impairments in panic disorder: a systematic review. J Affect Disord. 2014;167:268–84.
O’Toole MS, Pedersen AD. A systematic review of neuropsychological performance in social anxiety disorder. Nord J Psychiatry. 2011;65:147–61.
Yang Y et al. Cognitive impairment in generalized anxiety disorder revealed by event-related potential N270. Neuropsychiatr Dis Treat. 2015;11:1405–11.
Rickels K, Rynn M. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry. 2002;63:9–16.
Stewart SA. The effects of benzodiazepines on cognition. J Clin Psychiatry. 2005;66:9–13.
Russo A, Borrelli F. Bacopa monniera, a reputed nootropic plant: an overview. Phytomedicine. 2005;12:305–17.
Aguiar S, Borowski T. Neuropharmacological review of the nootropic herb Bacopa monnieri. Rejuvenation Res. 2013;16:313–26.
Singh HK, Dhawan BN. Neuropsychopharmacological effects of the Ayurvedic nootropic Bacopa monniera Linn (Brahmi). Indian J Pharmacol. 1997;29:359–65.
Nathan PJ et al. The acute effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy normal subjects. Hum Psychopharmacol. 2001;16:345–51.
Downey LA et al. An acute, double-blind, placebo-controlled crossover study of 320 mg and 640 mg doses of a special extract of Bacopa monnieri (CDRI 08) on sustained cognitive performance. Phytother Res. 2013;27:1407–13.
Becker RE. Therapy of the cognitive deficit in Alzheimers disease: the cholinergic system. In: Becker RE, Giabcobini E, editors. Cholinergic basis for Alzheimer therapy. Boston: Birkhauser; 1991. p. 1–22.
Bhattacharya SK et al. Antioxidant activity of Bacopa monniera in rat frontal cortex, striatum and hippocampus. Phytother Res. 2000;14:174–9.
Piyabhan P, Wetchateng T. Neuroprotective effects of Bacopa monnieri (brahmi) on novel object recognition and NMDAR1 immunodensity in the prefrontal cortex, striatum and hippocampus of sub-chronic phencyclidine rat model of schizophrenia. J Med Assoc Thai. 2014;97:S50–6.
Vollala VR, Upadhya S, Nayak S. Enhanced dendritic arborization of hippocampal CA3 neurons by Bacopa monniera extract treatment in adult rats. Rom J Morphol Embryol. 2011;52:879–86.
Bhattacharya SK, Ghosal S. Anxiolytic activity of a standardized extract of Bacopa monniera: an experimental study. Phytomedicine. 1998;5:77–82.
Benson S et al. An acute, double-blind, placebo-controlled cross-over study of 320 mg and 640 mg doses of Bacopa monnieri (CDRI 08) on multitasking stress reactivity and mood. Phytother Res. 2014;28:551–9.
Calabrese C et al. Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial. J Altern Complement Med. 2008;14:707–13.
Kumar T et al. Randomized control, double blind cross-over study to clinically assess the Rasayana effect of a standardized extract of Brahmi (Bacopa monniera) in adult human volunteers. Int J Pharm Pharm Sci. 2011;3(Suppl 4):263–6.
Sathyanarayanan V et al. Brahmi for the better? New findings challenging cognition and anti-anxiety effects of Brahmi (Bacopa monniera) in healthy adults. Psychopharmacology (Berl). 2013;227:299–306.
Sarris J, McIntyre E, Camfield DA. Plant-based medicines for anxiety disorders, Part 2: a review of clinical studies with supporting preclinical evidence. CNS Drugs. 2013;27:301–19.
Kongkeaw C et al. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. J Ethnopharmacol. 2014;151:528–35.
Pase MP et al. The cognitive-enhancing effects of bacopa monnieri: a systematic review of randomized, controlled human clinical trials. J Altern Complement Med. 2012;18:647–52.
Singh B et al. Biology and chemistry of Ginkgo biloba. Fitoterapia. 2008;79:401–18.
Christen Y, Maixent JM. What is Ginkgo biloba extract EGb 761? An overview from molecular biology to clinical medicine. Cell Mol Biol. 2002;48(6):601–11.
Maclennan KM, Darlington CL, Smith PF. The CNS effects of Ginkgo biloba extracts and ginkgolide B. Prog Neurobiol. 2002;67:235–57.
Diamond BJ et al. Ginkgo biloba extract: mechanisms and clinical indications. Arch Phys Med Rehabil. 2000;81:668–78.
Domingo MT et al. Inhibition by ginkgolides of the binding of [3H]PAF platelet-activating factor (PAF) to platelet membranes. In: Braquet P, editor. Ginkgolides. Barcelona: JR Prous; 1988. p. 79–84.
Hou Y et al. Anti-depressant natural flavonols modulate BDNF and beta amyloid in neurons and hippocampus of double TgAD mice. Neuropharmacology. 2010;58:911–20.
DeFeudis FV, Drieu K. “Stress-alleviating” and “vigilance-enhancing” actions of Ginkgo biloba extract (EGb 761). Drug Dev Res. 2004;62:1–25.
Belviranli M, Okudan N. The effects of Ginkgo biloba extract on cognitive functions in aged female rats: the role of oxidative stress and brain-derived neurotrophic factor. Behav Brain Res. 2015;278:453–61.
Ward CP et al. Ginkgo biloba extract: cognitive enhancer or antistress buffer. Pharmacol Biochem Behav. 2002;72:913–22.
Satyan KS et al. Effect of Ginkgolic acid conjugates on the brain monoamines and metabolites in rodents. Biogenic Amines. 1997;13:143–51.
Hartley DE et al. Effects on cognition and mood in postmenopausal women of 1-week treatment with Ginkgo biloba. Pharmacol Bioch Behav. 2003;75:711–20.
Woelk H et al. Ginkgo biloba special extract EGb 761® in generalized anxiety disorder and adjustment disorder with anxious mood: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res. 2007;41:472–80.
Gavrilova SI et al. Efficacy and safety of Ginkgo biloba extract EGb 761® in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo-controlled, double-blind, multicenter trial. Int J Geriatr Psychiatry. 2014;29:1087–95.
Hoerr R. Behavioural and psychological symptoms of dementia (BPSD): effects of EGb 761®. Pharmacopsychiatry. 2003;36(Suppl 1).
Vellas B et al. Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol. 2012;11:851–9.
Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2007;2.
Brondino N et al. A systematic review and meta-analysis of ginkgo biloba in neuropsychiatric disorders: from ancient tradition to modern-day medicine. Evid Based Complement Alternat Med. 2013;2013.
Scholey A et al. Investigation of a Melissa officinalis special extract on Cognition II: human study – Lemon balm extract administered in confectionary bars. Agro Food Ind Hi-Tech. 2015;26:12–4.
Kennedy DO, Scholey AB. The psychopharmacology of European herbs with cognition-enhancing properties. Curr Pharm Des. 2006;12:4613–23.
Kennedy DO et al. Modulation of mood and cognitive performance following acute administration of single doses of Melissa officinalis (Lemon balm) with human CNS nicotinic and muscarinic receptor-binding properties. Neuropsychopharmacology. 2003;28:1871–81.
Awad R et al. Bioassay-guided fractionation of lemon balm (Melissa officinalis L.) using an in vitro measure of GABA transaminase activity. Phytother Res. 2009;23:1075–81.
Buchwald-Werner S, Vazquez I, Röchter S. Investigation of a Melissa officinalis special extract on Cognition I: in vitro study on muscarinic properties. Agro Food Ind Hi-Tech. 2015;26:34–6.
Scholey A et al. Anti-stress effects of lemon balm-containing foods. Nutrients. 2014;6:4805–21.
Lin SH et al. A medicinal herb, Melissa officinalis L. ameliorates depressive-like behavior of rats in the forced swimming test via regulating the serotonergic neurotransmitter. J Ethnopharmacol. 2015;175:266–72.
Ibarra A et al. Effects of chronic administration of Melissa officinalis L. extract on anxiety-like reactivity and on circadian and exploratory activities in mice. Phytomedicine. 2010;17:397–403.
Yoo DY et al. Effects of Melissa officinalis L. (Lemon Balm) extract on neurogenesis associated with serum corticosterone and GABA in the mouse dentate gyrus. Neurochem Res. 2011;36:250–7.
Taiwo AE et al. Anxiolytic and antidepressant-like effects of Melissa officinalis (lemon balm) extract in rats: influence of administration and gender. Indian J Pharmacol. 2012;44:189–92.
Raines T et al. Investigation of the anxiolytic effects of luteolin, a lemon balm flavonoid in the male Sprague-Dawley rat. AANA J. 2009;77:33–6.
Kennedy DO et al. Modulation of mood and cognitive performance following acute administration of Melissa officinalis (lemon balm). Pharmacol Biochem Behav. 2002;72:953–64.
Kennedy DO, Little W, Scholey AB. Attenuation of laboratory-induced stress in humans after acute administration of Melissa officinalis (lemon balm). Psychosom Med. 2004;66:607–13.
Cases J et al. Pilot trial of Melissa officinalis L. leaf extract in the treatment of volunteers suffering from mild-to-moderate anxiety disorders and sleep disturbances. Med J Nutrition Metab. 2011;4:211–8.
Ballard CG et al. Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with Melissa. J Clin Psychiatry. 2002;63:553–8.
Akhondzadeh S et al. Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer’s disease: a double blind, randomised, placebo controlled trial. J Neurol Neurosur Psychiatry. 2003;74:863–6.
Burns A et al. A double-blind placebo-controlled randomized trial of melissa officinalis oil and donepezil for the treatment of agitation in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2011;31:158–64.
Feng L et al. Cognitive function and tea consumption in community dwelling older Chinese in Singapore. J Nutr Health Aging. 2010;14:433–8.
Kuriyama S et al. Green tea consumption and cognitive function: a cross-sectional study from the Tsurugaya Project 1. Am J Clin Nutr. 2006;83:355–61.
Ng TP et al. Tea consumption and cognitive impairment and decline in older Chinese adults. Am J Clin Nutr. 2008;88:224–31.
Hozawa A et al. Green tea consumption is associated with lower psychological distress in a general population: the Ohsaki Cohort 2006 Study. Am J Clin Nutr. 2009;90:1390–6.
Sharangi AB. Medicinal and therapeutic potentialities of tea (Camellia sinensis L.) – a review. Food Res Int. 2009;42:529–35.
Graham HN. Green tea composition, consumption, and polyphenol chemistry. Prev Med. 1992;21:334–50.
Singh BN, Shankar S, Srivastava RK. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol. 2011;82:1807–21.
Lu K et al. The acute effects of L-theanine in comparison with alprazolam on anticipatory anxiety in humans. Hum Psychopharmacol. 2004;19:457–65.
Yokogoshi H et al. Effect of theanine, r-glutamylethylamide, on brain monoamines and striatal dopamine release in conscious rats. Neurochem Res. 1998;23:667–73.
Lardner AL. Neurobiological effects of the green tea constituent theanine and its potential role in the treatment of psychiatric and neurodegenerative disorders. Nutr Neurosci. 2014;17:145–55.
Heese T et al. Anxiolytic effects of L-theanine: a component of green tea-when combined with midazolam, in the male Sprague-Dawley rat. AANA J. 2009;77:445–9.
Kelly SP et al. L-theanine and caffeine in combination affect human cognition as evidenced by oscillatory alpha-band activity and attention task performance. J Nutr. 2008;138.
Wise LE et al. L-theanine attenuates abstinence signs in morphine-dependent rhesus monkeys and elicits anxiolytic-like activity in mice. Pharmacol Biochem Behav. 2012;103:245–52.
Banji D et al. Amelioration of behavioral aberrations and oxidative markers by green tea extract in valproate induced autism in animals. Brain Res. 2011;1410:141–51.
Kaur T et al. Effects of green tea extract on learning, memory, behavior and acetylcholinesterase activity in young and old male rats. Brain Cogn. 2008;67:25–30.
Bitu Pinto N et al. Neuroprotective properties of the standardized extract from Camellia sinensis (Green Tea) and its main bioactive components, Epicatechin and Epigallocatechin Gallate, in the 6-OHDA model of Parkinson’s Disease. Evid Based Complement Alternat Med. 2015;2015.
Vignes M et al. Anxiolytic properties of green tea polyphenol (−)-epigallocatechin gallate (EGCG). Brain Res. 2006;1110:102–15.
Stringer M et al. Low dose EGCG treatment beginning in adolescence does not improve cognitive impairment in a Down syndrome mouse model. Pharmacol Biochem Behav. 2015:70–9.
Dodd FL et al. A double-blind, placebo-controlled study evaluating the effects of caffeine and L-theanine both alone and in combination on cerebral blood flow, cognition and mood. Psychopharmacology (Berl). 2015;232:2563–76.
Rogers PJ et al. Time for tea: mood, blood pressure and cognitive performance effects of caffeine and theanine administered alone and together. Psychopharmacology (Berl). 2008;195:569–77.
Camfield DA et al. Acute effects of tea constituents L-theanine, caffeine, and epigallocatechin gallate on cognitive function and mood: a systematic review and meta-analysis. Nutr Rev. 2014;72:507–22.
Ritsner MS et al. L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study. J Clin Psychiatry. 2011;72(1):34–42.
White DJ et al. Anti-stress, behavioural and magnetoencephalography effects of an l-theanine-based nutrient drink: a randomised, double-blind, placebo-controlled, crossover trial. Nutrients. 2016;8.
Yoto A et al. Effects of L-theanine or caffeine intake on changes in blood pressure under physical and psychological stresses. J Physiol Anthropol. 2012;31:28.
Kimura K et al. l-Theanine reduces psychological and physiological stress responses. Biol Psychol. 2007;74(1):39–45.
Scholey A et al. Acute neurocognitive effects of epigallocatechin gallate (EGCG). Appetite. 2012;58:767–70.
Wightman EL et al. Epigallocatechin gallate, cerebral blood flow parameters, cognitive performance and mood in healthy humans: a double-blind, placebo-controlled, crossover investigation. Hum Psychopharmacol. 2012;27:177–86.
Borgwardt S et al. Neural effects of green tea extract on dorsolateral prefrontal cortex. Eur J Clin Nutr. 2012;66:1187–92.
Perry E, Howes MJR. Medicinal plants and dementia therapy: herbal hopes for brain aging? CNS Neurosci Ther. 2011;17:683–98.
Perry NSL et al. In-vitro inhibition of human erythrocyte acetylcholinesterase by Salvia lavandulaefolia essential oil and constituent terpenes. J Pharm Pharmacol. 2000;52:895–902.
Savelev S et al. Synergistic and antagonistic interactions of anticholinesterase terpenoids in Salvia lavandulaefolia essential oil. Pharmacol Biochem Behav. 2003;75:661–8.
Perry NSL et al. Salvia lavandulaefolia essential oil inhibits cholinesterase in vivo. Phytomedicine. 2002;9:48–51.
Savelev SU, Okello EJ, Perry EK. Butyryl- and acetyl-cholinesterase inhibitory activities in essential oils of Salvia species and their constituents. Phytother Res. 2004;18:315–24.
Perry NSL et al. Salvia for dementia therapy: review of pharmacological activity and pilot tolerability clinical trial. Pharmacol Biochem Behav. 2003;75:651–9.
Herrera-Ruiz M et al. Antidepressant and anxiolytic effects of hydroalcoholic extract from Salvia elegans. J Ethnopharmacol. 2006;107:53–8.
Mora S et al. The hydroalcoholic extract of Salvia elegans induces anxiolytic- and antidepressant-like effects in rats. J Ethnopharmacol. 2006;106:76–81.
Hosseinzadeh H, Danaee A, Ziaee T. Anti-anxiety effect of aqueous and ethanolic extracts of Salvia leriifolia Benth. leaves in mice using elevated plus maze. J Med Plants. 2008;7:25–36.
Rabbani M et al. Anxiolytic effects of Salvia reuterana Boiss. on the elevated plus-maze model of anxiety in mice. J Ethnopharmacol. 2005;101:100–3.
Liu AD et al. Anxiolytic effect of essential oils of Salvia miltiorrhiza in rats. Int J Clin Exp Med. 2015;8:12756–64.
Tildesley NTJ et al. Positive modulation of mood and cognitive performance following administration of acute doses of Salvia lavandulaefolia essential oil to healthy young volunteers. Physiol Behav. 2005;83:699–709.
Kennedy DO et al. Effects of cholinesterase inhibiting sage (Salvia officinalis) on mood, anxiety and performance on a psychological stressor battery. Neuropsychopharmacology. 2006;31:845–52.
Kennedy DO et al. Monoterpenoid extract of sage (Salvia lavandulaefolia) with cholinesterase inhibiting properties improves cognitive performance and mood in healthy adults. J Psychopharmacol. 2011;25:1088–100.
Eidi M, Eidi A, Bahar M. Effects of Salvia officinalis L. (sage) leaves on memory retention and its interaction with the cholinergic system in rats. Nutrition. 2006;22:321–6.
Tildesley NTJ et al. Salvia lavandulaefolia (Spanish sage) enhances memory in healthy young volunteers. Pharmacol Biochem Behav. 2003;75:669–74.
Scholey AB et al. An extract of Salvia (sage) with anticholinesterase properties improves memory and attention in healthy older volunteers. Psychopharmacology (Berl). 2008;198:127–39.
Akhondzadeh S et al. Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer’s disease: a double blind, randomized and placebo-controlled trial. J Clin Pharm Ther. 2003;28:53–9.
El Omri A et al. Rosmarinus officinalis polyphenols activate cholinergic activities in PC12 cells through phosphorylation of ERK1/2. J Ethnopharmacol. 2010;131:451–8.
Orhan I et al. Inhibitory effect of Turkish Rosmarinus officinalis L. on acetylcholinesterase and butyrylcholinesterase enzymes. Food Chem. 2008;108:663–8.
Kovar KA et al. Blood levels of 1,8-cineole and locomotor activity of mice after inhalation and oral administration of rosemary oil. Planta Med. 1987;53:315–8.
Ozarowski M et al. Rosmarinus officinalis L. leaf extract improves memory impairment and affects acetylcholinesterase and butyrylcholinesterase activities in rat brain. Fitoterapia. 2013;91:261–71.
Heuberger E et al. Physiological and behavioral effects of 1,8-cineol and (±)-linalool: a comparison of inhalation and massage aromatherapy. Nat Prod Commun. 2008;3:1103–10.
Moss M et al. Aromas of rosemary and lavender essential oils differentially affect cognition and mood in healthy adults. Int J Neurosci. 2003;113:15–38.
Diego MA et al. Aromatherapy positively affects mood, EEG patterns of alertness and math computations. Int J Neurosci. 1998;96:217–24.
Tsang HW, Ho TY. A systematic review on the anxiolytic effects of aromatherapy on rodents under experimentally induced anxiety models. Rev Neurosci. 2010;21:141–52.
Ferlemi AV et al. Rosemary tea consumption results to anxiolytic- and anti-depressant-like behavior of adult male mice and inhibits all cerebral area and liver cholinesterase activity; phytochemical investigation and in silico studies. Chem Biol Interact. 2015;237:47–57.
Abdelhalim A et al. Antidepressant, anxiolytic and antinociceptive activities of constituents from rosmarinus officinalis. J Phar Pharm Sci. 2015;18:448–59.
McCaffrey R, Thomas DJ, Kinzelman AO. The effects of lavender and rosemary essential oils on test-taking anxiety among graduate nursing students. Holist Nurs Pract. 2009;23:88–93.
Rho KH et al. Effects of aromatherapy massage on anxiety and self-esteem in Korean elderly women: a pilot study. Int J Neurosci. 2006;116:1447–55.
Lee YL et al. A systematic review on the anxiolytic effects of aromatherapy in people with anxiety symptoms. J Altern Complement Med. 2011;17:101–8.
Burnett KM, Solterbeck LA, Strapp CM. Scent and mood state following an anxiety-provoking task. Psychol Rep. 2004;95:707–22.
Field T. Massage therapy research review. Complement Ther Clin Pract. 2014;20(4=):224–9.
Keeratitanont K et al. The efficacy of traditional Thai massage for the treatment of chronic pain: a systematic review. Complement Ther Clin Pract. 2015;21:26–32.
Yuan SLK, Matsutani LA, Marques AP. Effectiveness of different styles of massage therapy in fibromyalgia: a systematic review and meta-analysis. Man Ther. 2015;20:257–64.
Morin AK. Off-label use of atypical antipsychotic agents for treatment of insomnia. Mental Health Clinician (March 2014-Trends in Sedative-Hypnotic Therapy). 2014;4:65–72.
APA. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.
Beck AT. Cognitive therapy: basics and beyond. New York: Guilford Press; 1995.
Clark, D.A. and A.T. Beck, Cognitive therapy of anxiety disorders: science and practice. 2010, New York: Guilford Publications.
Barlow DH. Clinical handbook of psychological disorders: a step-by-step treatment manual. 4th ed. New York: The Guilford Press; 2008.
Bennett-Levy J et al. Oxford guide to behavioural experiments in cognitive therapy. Oxford, UK: Oxford University Press; 2004.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Steiner, G.Z., Mathersul, D.C. (2017). Cognitive Anxiolytics. In: Camfield, D., McIntyre, E., Sarris, J. (eds) Evidence-Based Herbal and Nutritional Treatments for Anxiety in Psychiatric Disorders. Springer, Cham. https://doi.org/10.1007/978-3-319-42307-4_4
Download citation
DOI: https://doi.org/10.1007/978-3-319-42307-4_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-42305-0
Online ISBN: 978-3-319-42307-4
eBook Packages: MedicineMedicine (R0)